Impact of Antifibrotic Dose Modifications on Idiopathic Pulmonary Fibrosis Outcomes: Insights from Real-World Data
Highlight
1. Dose reductions and discontinuations of antifibrotic medications nintedanib and pirfenidone are common in clinical practice due to poor tolerability in patients with IPF.
2. Real-world data from the Pulmonary Fibrosis Foundation Registry and Duke University Health System show no significant difference in disease progression risk between patients on full dose antifibrotics and those who reduce or stop therapy.
3. Disease progression rates remain high despite antifibrotic use, emphasizing the urgent need for more effective and better-tolerated treatment options.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.